Vertex Pharmaceuticals's Total Assets for the quarter that ended in Dec. 2023 was $22,730 Mil.
During the past 12 months, Vertex Pharmaceuticals's average Total Assets Growth Rate was 56.10% per year.
During the past 3 years, the average Total Assets Growth Rate was 31.20% per year.
During the past 5 years, the average Total Assets Growth Rate was 26.50% per year.
During the past 10 years, the average Total Assets Growth Rate was 30.20% per year.
During the past 13 years, Vertex Pharmaceuticals's highest 3-Year average Total Assets Growth Rate was 102.70%. The lowest was -33.50%. And the median was 21.50%.
Total Assets is connected with ROA %. Vertex Pharmaceuticals's annualizedROA % for the quarter that ended in Dec. 2023 was 17.43%. Total Assets is also linked to Revenue through Asset Turnover. Vertex Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 was 0.11.
Vertex Pharmaceuticals Total Assets Historical Data
The historical data trend for Vertex Pharmaceuticals's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Vertex Pharmaceuticals Annual Data
Trend
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Total Assets
8,318.47
11,751.80
13,432.50
18,150.90
22,730.20
Vertex Pharmaceuticals Quarterly Data
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Mar22
Jun22
Sep22
Dec22
Mar23
Jun23
Sep23
Dec23
Total Assets
18,150.90
18,974.20
20,349.20
21,726.20
22,730.20
Vertex Pharmaceuticals Total Assets Calculation
Total Assets are all the assets a company owns.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Vertex Pharmaceuticals's Total Assets for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vertex Pharmaceuticals (NAS:VRTX) Total Assets Explanation
Note:
The Net Income data used here is four times the quarterly (Dec. 2023) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Vertex Pharmaceuticals's Asset Turnover for the quarter that ended in Dec. 2023 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Vertex Pharmaceuticals Total Assets Related Terms
Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Total Assets provided by GuruFocus.com. Please click on the following links to see related term pages.
Vertex Pharmaceuticals (Vertex Pharmaceuticals) Business Description
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
VRTX has been successfully added to your 